成人大片

May 6th - Ami Bhatt

Co-hosted with the听

May 6 , 2025| 4:00pm - 5:00 pm
Hybrid event - registration required

Free In-person:听Faculty Club
3450 McTavish,听Montreal
Online:听Zoom link sent to registered participants

Networking Reception听post seminar

Program:

Talk Title: 鈥淛ump, Flip and Hide鈥�
Ami S. Bhatt, MD, PhD
Professor of Medicine and Genetics
Stanford University

Dr Ami Bhatt is a Professor at Stanford University in the Departments of Medicine (Hematology; Blood & Marrow Transplantation) and Genetics. A physician scientist with a strong interest in microbial genomics and metagenomics, she received her MD and PhD from the University of California, San Francisco (Alpha Omega Alpha), followed by residency, chief residency and fellowship training at Brigham and Women鈥檚 Hospital and the Dana-Farber Cancer Center at Harvard Medical School. She joined the faculty at Stanford University in 2014 after completing a post-doctoral fellowship focused on genomics at the Broad Institute of Harvard and MIT.

Prof. Bhatt鈥檚 laboratory develops and applies novel molecular and computational tools to study strain level dynamics of the human microbiome, to understand how microbial genomes change over time and predict the functional output of microbiomes. She is keenly interested to understand how microbes use microproteins to 鈥渢alk鈥� to one another and to human cells, and to leverage this understanding to improve health and treat diseases. Her work is actively being translated from bench to bedside; for example, enzymes that her lab mined from microbes are now being developed these as human genome editing/engineering tools in a start-up company that she co-founded.

She has received multiple awards including the Chen Award of Excellence from the Human Genome Organisation (HUGO), the Distinguished Investigator Award from the Paul Allen Foundation, and the Sloan Foundation Fellowship; she is also an elected member of the American Society of Clinical Investigation and the 2024 American Society of Hematology William Dameshek Prize winner. She has disseminated her distinguished research globally, delivering more than 160 invited presentations. A committed mentor, she has served as the primary research advisor to a diverse cohort of over 60 undergraduate, medical, PhD, and post-doctoral scholars.

Dr. Bhatt is also leading efforts to ensure equity and global access in research and medicine. She carries out research with the H3Africa Genomics Consortium, volunteers for the nonprofit she co-founded in 2012, Global Oncology, and serves as the Director for Global Oncology for Stanford鈥檚 Center for Innovation in Global Health. She is working to improve collaboration and exchange between scholars at Stanford and those in South Asia, Africa, and beyond. She continues to practice clinical medicine, caring for patients with hematological disorders in the hospital setting. Outside of work, she has been diligently iterating on her vegan ramen recipe.

Abstract:

To fully appreciate how microbes can impact health, we must appreciate the complexity and adaptability of microbes themselves. Bacteria may be small, unicellular and have compact genomes 鈥� but the vast array of circumstances they can adapt to, thrive in, and overcome with their limited DNA codebook is mind-boggling. Our lab鈥檚 research program focuses on measuring microbes and microbial genomes carefully and trying to explore and understand bacteria at a level beyond their simple taxonomy. In this presentation, I will describe how advances in molecular and computational approaches have enabled a greater understanding of structural variation and mobile genetic elements (ranging from insertion sequences to integrated prophages) and their role in microbial evolution and adaptation. I will share specific examples of how these types of events can lead to evolution of antimicrobial resistance in short, clinical timescales.

November 21st - Mark Miller

Seminar + Social WAAW special

Co-hosted with the听JD Maclean Centre of Tropical and Geographic Medicine听

November 21, 2024 | 4:00pm - 5:15 pm
Hybrid event - registration required

Free In-person:听RI-MUHC - Cruess Auditorium (Block E, ES1.1129)
1001 Decarie Boulevard, Montreal
Online:听Zoom link sent to registered participants

Networking Reception听

Program:

"Antimicrobial resistance: the silent pandemic and the role of diagnostics in the battle to sustain antibiotics and save lives."听
Mark Miller, MD, FRCP(C) | Independent Industry Consultant, Internist, Microbiologist, Infectious Diseases Clinician
Former Executive VP and Chief Medical Officer, bioM茅rieux SA, Lyon, France

Panel Discussion:

• Mark Miller,听Independent Industry Consultant
• Peter J Dailey, Berkeley School of Public Health, University of California
• David Juncker,听Chair Biomedical Engineering Dept., 成人大片 University

About our speaker:

Dr. Miller, originally from Montreal, Canada, has had a unique 35-year medical career which has been a high-level combination of clinical, academic, and industrial experiences. He is a physician with training and certification in Internal Medicine, Infectious Diseases, and Medical Microbiology. In addition, he possesses a Master鈥檚 degree in Epidemiology & Biostatistics.

During his hospital-based 25-year academic career, he was the Chairman of 4 departments containing over 70 people in: Clinical Infectious Diseases (ID), Clinical Microbiology (Micro), ID/Micro Research, and Infection Prevention & Control. He was a full-time clinician, administrator, and researcher (novel antiinfectives and vaccines, innovative infectious disease diagnostics, and the epidemiology of healthcare-associated infections). In the latter role, he was a primary or co-author of over 150 peer-reviewed publications and over 160 presentations and was the co-discoverer of the novel hyper-virulent C. difficile strain NAP1/027 which was described in the New England Journal of Medicine in 2005. He was granted a full Professorship in the Department of Medicine at 成人大片 University in 2011.

In his subsequent 12-year career (2012-2024) as Chief Medical Officer and Executive Vice President at the French head office of bioM茅rieux, a global in vitro diagnostics company, he created from scratch the departments of Medical Affairs, Public & Government Affairs, Patient Value Strategy, and Companion Diagnostics. For these functions, he oversaw more than 140 people and an annual budget of approximately 26 million Euros, with a focus on defining, advancing, and demonstrating the medical value and health benefits of diagnostics for improving outcomes for patients, healthcare institutions and the entire medical system.

His distinctive academic-industrial knowledge and experiences have allowed him to participate in many global, national and regional activities to improve the success of translational research to reach patients, improve global capabilities for diagnostic biopreparedness related to infectious pathogens, and to be involved in the creation of dozens of clinical diagnostics for the benefit of patients world-wide.

Currently semi-retired since January 2024, he is an independent consultant or on the Scientific Advisory Board for several companies involved with antimicrobials, vaccines, and infectious disease diagnostics.

About our panelists:

Dr. Peter J. Dailey is a microbiologist who an adjunct professor at the University of California, Berkeley School of Public Health. He is an independent consultant for CARB-X and FIND 鈥� the global alliance for diagnostics. He has 35 years of experience in infectious disease, primarily in the research and development of infectious disease molecular diagnostics. He has led the research and development of over 20 commercial diagnostic and blood-screening assays for infectious diseases at Chiron, Roche Diagnostics, and Cepheid.

David Juncker is a Canada Research Chair in Bioengineering and Professor, serving as Chair of Biomedical Engineering at 成人大片 University. He earned a Diploma in Electronics-Physics from the Institute of Microtechnology at the University of Neuchatel (now part of EPFL). After a year at Japan's National Research Laboratory of Metrology, he completed his PhD at IBM Zurich under Dr. Delamarche, followed by a postdoc at ETHZ. Joining 成人大片 as faculty, his lab focuses on pioneering micro- and nanobioengineering technologies to improve health. Juncker's team has developed innovations like microfluidic probes, thread-based microfluidics, and multiplexed, cross-reactivity-free immunoassays, leading to two spin-offs, including Nomic Bio. now explores extracellular vesicles and lipid nanoparticles, developing novel technologies for their analysis.

听